Physician profile
Michael J Lynch
NPI 1619915873
$1,108.33
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $154 · 2021: $312 · 2022: $130.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $348.63 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $132.94 | 2019 | |
| Amarin Pharma, INC. | $114.83 | 2019-2020 | |
| Allergan, INC. | $90.59 | 2019-2020 | |
| Glaxosmithkline, LLC. | $85.90 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $60.39 | 2019 | |
| Amgen INC. | $58.45 | 2019-2020 | |
| Pfizer INC. | $49.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $48.51 | 2021-2022 | |
| Novo Nordisk INC | $32.14 | 2019 | |
| Genentech USA, INC. | $20.28 | 2020 | |
| Mylan Specialty L.P. | $17.45 | 2019 | |
| Sanofi Pasteur INC. | $14.07 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.04 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.20 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $11.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.